New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended
Open Access
- 14 December 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7693
Abstract
The overall low-quality evidence concerning the clinical benefits of different antibiotic regimens for the treatment of infective endocarditis (IE), which has made it difficult to strongly support or reject any regimen of antibiotic therapy, has led to a discrepancy between the available guidelines and clinical practice. In this complex scenario, very recently published guidelines have attempted to fill this gap. Indeed, in recent years several antimicrobials have entered the market, including ceftobiprole, ceftaroline, and the long-acting lipoglycopeptides dalbavancin and oritavancin. Despite being approved for different indications, real-world data on their use for the treatment of IE, alone or in combination, has accumulated over time. Furthermore, an old antibiotic, fosfomycin, has gained renewed interest for the treatment of complicated infections such as IE. In this narrative review, we focused on new antimicrobials and therapeutic strategies that we believe may provide important contributions to the advancement of Gram-positive IE treatment, providing a summary of the current in vitro, in vivo, and clinical evidence supporting their use in clinical practice.Keywords
This publication has 194 references indexed in Scilit:
- Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial ActivityAntimicrobial Agents and Chemotherapy, 2012
- High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus EndocarditisAntimicrobial Agents and Chemotherapy, 2012
- Pharmacodynamic Evaluation of the Activity of Antibiotics against Hemin- and Menadione-Dependent Small-Colony Variants of Staphylococcus aureus in Models of Extracellular (Broth) and Intracellular (THP-1 Monocytes) InfectionsAntimicrobial Agents and Chemotherapy, 2012
- In Vivo Synergism of Ceftobiprole and Vancomycin against Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2011
- Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-Kill AssayAntimicrobial Agents and Chemotherapy, 2010
- Ceftobiprole Is Superior to Vancomycin, Daptomycin, and Linezolid for Treatment of Experimental Endocarditis in Rabbits Caused by Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2010
- In Vivo Activity of a Novel Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin, Ceftaroline, against Vancomycin-Susceptible and -Resistant Enterococcus faecalis Strains in a Rabbit Endocarditis Model: a Comparative Study with Linezolid and VancomycinAntimicrobial Agents and Chemotherapy, 2009
- Activities of Ceftobiprole, Linezolid, Vancomycin, and Daptomycin against Community-Associated and Hospital-Associated Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2008
- In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis ModelAntimicrobial Agents and Chemotherapy, 2007
- Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis , Including β-Lactamase-Producing and Vancomycin-Resistant IsolatesAntimicrobial Agents and Chemotherapy, 2007